Literature DB >> 11259836

The role of gamma-scintigraphy in oral drug delivery.

I R Wilding1, A J Coupe, S S Davis.   

Abstract

The gastrointestinal tract is usually the preferred site of absorption for most therapeutic agents, as seen from the standpoints of convenience of administration, patient compliance and cost. In recent years there has been a tendency to employ sophisticated systems that enable controlled or timed release of a drug, thereby providing a better dosing pattern and greater convenience to the patient. Although much about the performance of a system can be learned from in vitro release studies using conventional and modified dissolution methods, evaluation in vivo is essential in product development. The non-invasive technique of gamma-scintigraphy has been used to follow the gastrointestinal transit and release characteristics of a variety of pharmaceutical dosage forms. Such studies provide an insight into the fate of the delivery system and its integrity and enable the relationship between in vivo performance and resultant pharmacokinetics to be examined (pharmacoscintigraphy).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11259836     DOI: 10.1016/s0169-409x(00)00135-6

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  22 in total

1.  Study on of bioadhesive property of carbomer 934 by a gamma camera in vivo.

Authors:  Jie Fu; Xun Sun; Zhi-Rong Zhang
Journal:  World J Gastroenterol       Date:  2002-02       Impact factor: 5.742

2.  Experimental design for the formulation and optimization of novel cross-linked oilispheres developed for in vitro site-specific release of Mentha piperita oil.

Authors:  Wilbert Sibanda; Viness Pillay; Michael P Danckwerts; Alvaro M Viljoen; Sandy van Vuuren; Riaz A Khan
Journal:  AAPS PharmSciTech       Date:  2004-03-12       Impact factor: 3.246

3.  Optimization of LY545694 tosylate controlled release tablets through pharmacoscintigraphy.

Authors:  Evelyn D Lobo; Mark D Argentine; David C Sperry; Alyson Connor; John McDermott; Lloyd Stevens; Ahmad Almaya
Journal:  Pharm Res       Date:  2012-06-14       Impact factor: 4.200

Review 4.  Biomagnetic methods: technologies applied to pharmaceutical research.

Authors:  Luciana A Corá; Madileine F Américo; Ricardo B Oliveira; Cristina H R Serra; Oswaldo Baffa; Raul C Evangelista; Giselle F Oliveira; José Ricardo Aruda Miranda
Journal:  Pharm Res       Date:  2010-10-15       Impact factor: 4.200

5.  Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation.

Authors:  M Brunner; S Ziegler; A F D Di Stefano; P Dehghanyar; K Kletter; M Tschurlovits; R Villa; R Bozzella; G Celasco; L Moro; A Rusca; R Dudczak; M Müller
Journal:  Br J Clin Pharmacol       Date:  2006-01       Impact factor: 4.335

Review 6.  In vitro and in vivo models for the study of oral delivery of nanoparticles.

Authors:  Jennifer M Gamboa; Kam W Leong
Journal:  Adv Drug Deliv Rev       Date:  2013-02-13       Impact factor: 15.470

7.  Design and evaluation of matrix base with sigmoidal release profile for colon-specific delivery using a combination of Eudragit and non-ionic cellulose ether polymers.

Authors:  Laila Fatima Ali Asghar; Sajeev Chandran
Journal:  Drug Deliv Transl Res       Date:  2011-04       Impact factor: 4.617

Review 8.  Applications of stable isotopes in clinical pharmacology.

Authors:  Reinout C A Schellekens; Frans Stellaard; Herman J Woerdenbag; Henderik W Frijlink; Jos G W Kosterink
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

Review 9.  Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.

Authors:  Staffan Edsbäcker; Tommy Andersson
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

10.  Magnetic resonance imaging for the in vivo evaluation of gastric-retentive tablets.

Authors:  Andreas Steingoetter; Dominik Weishaupt; Patrick Kunz; Karsten Mäder; Hans Lengsfeld; Miriam Thumshirn; Peter Boesiger; Michael Fried; Werner Schwizer
Journal:  Pharm Res       Date:  2003-12       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.